Abstract:Abstract Background KRAS is the most frequently mutated gene in pancreatic ductal adenocarcinoma (PDAC). Over the past decade, targeting KRAS has emerged as a promising approach for PDAC treatment. However, the associations between KRAS mutations status and comutation landscape with clinical outcomes remain understudied. We investigated the impact of KRAS mutant allelic status and genomic co-mutations with clinical outcomes. Methods 803 patients with PDAC who underwent CLIA somatic tumor mutation testing at MD Anderson Cancer Center (MDACC) from 1997 to 2023 were identified after an IRB approval. Tumor genomic alterations, demographics, clinical, molecular, and pathological data were extracted from electronic medical records and tumor registry through the Palantir Foundry platform. An external cohort from PanCAN’s Know Your Tumor® dataset with 408 patients served as the validation cohort. Overall Survival (OS) was calculated from the date of initial diagnosis to death or last follow-up. Pearson’s chi-squared tests (or Fisher’s exact tests) were used to determine the association between groups. The Kaplan-Meier method was used to estimate the median OS. Results 703 patients had KRAS gene included in the mutation testing at MDACC from 1997 to 2023. KRAS was the top mutated gene (82%), followed by TP53 (69%), then CDKN2A (20%). In KRAS mutant patients, G12D was the most common variant (39%), followed by G12V (31%), then G12R (14%), and Q61 (6%). In patients tested with multi-gene panels, a co-mutation analysis revealed that the most common co-occurring mutations with KRAS mutation was TP53 (75%), followed by CDKN2A (22%), SMAD4 (14%) and ARID1A (10%). The median follow-up was 41 months and median OS was 19 months in the overall population. KRAS mutation status and subtypes was prognostic of OS (p<0.001). Patients with KRAS wildtype had median OS of 38 months and KRASG12R had median OS of 34 months (HR:1.0, 95% CI 0.71-1.5, p=0.88), while patients with KRASQ61 had worst median OS of 20 months (HR: 1.9, 95% CI 1.2-3.0, p=0.006) and KRASG12D had median OS of 22 months (HR: 1.7, 95% CI 1.3-2.3, p<0.001). Similar findings were observed in patients with stage IV disease (n=302), KRASG12D remained associated with significantly worse OS (HR= 1.7, 95% CI 1.1-2.6, p=0.009). There was a significant enrichment of KRASG12D mutation in metastatic disease compared to localized disease (stage I-III) (OR: 1.7, 95% CI 1.2-2.4, p=0.001) and enrichment of KRASG12R mutation in well and moderately differentiated tumors versus poorly differentiated tumors (OR: 1.7, 95% CI 1.05-2.99, p=0.04). In the external cohort (PanCAN’s Know Your Tumor® dataset), similar findings were observed. KRASG12R was associated with longer median OS (32 months), while KRASQ61 (16 months, HR: 2.6, 95% CI 0.88-7.8, p=0.02) and KRASG12D (23 months, HR: 1.68, 95% CI 1.06-2.65, p=0.04) were associated with significantly worse median OS. Conclusion Allele specific associations of KRAS mutation with clinical outcomes were identified in PDAC. We found better OS with G12R and worse OS with G12D and Q61. Citation Format: Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl, Paul Edelkamp, Kristin Alfaro-Munoz, Ray Chacko, Jennifer Peterson, Brandon Smaglo, Robert Wolff, Shubham Pant, Michael Lee, Jason Willis, Michael Overman, Sudheer Doss, Lynn Matrisian, Mark Hurd, Rebecca Snyder, Matthew Katz, Huamin Wang, Anirban Maitra, John Paul Shen, Dan Zhao. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr C098.

Abstract B009: Analysis of the KRAS mutation spectrum in Black/African American and White/European lung adenocarcinoma patients, and its association with patient survival

Abstract C171: Identifying cancer driver mutation signatures in lung adenocarcinoma from Black/African American individuals: Addressing cancer health disparities

Abstract C168: Developing lung adenocarcinoma cell lines to mitigate lung cancer health disparities

Abstract C169: Investigating the effects of ancestry in KRAS mediated lung adenocarcinoma: Exploring intratumoral heterogeneity and mitochondrial dynamics

Abstract 1004: Establishing lung adenocarcinoma cell lines to mitigate lung cancer health disparities

Abstract A106: Disparities in the presence of driver mutations and response to tyrosine kinase inhibitors in young patients with lung cancer

Abstract C154: Clinical, genomic, and socioeconomic factors underlying low survival rates from colorectal cancer in African American patients

Abstract 1746: KRAS mutant lung adenocarcinoma is associated with distinct mutational signature profiles

Abstract 2151: Additional impact of genetic ancestry over self-reported race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer

Abstract C021: Racial and socioeconomic disparities in molecular diagnostics for NSCLC patients

Abstract C098: Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Abstract B004: Multi-omics profiling to identify mechanisms of resistance to KRAS inhibition: A comparative study on colorectal and lung cancer

Racial and Ethnic Disparities in Lung Adenocarcinoma Survival: A Competing-Risk Model.

Abstract 6120: Genomic profiling of KRAS and EGFR -altered non-squamous non-small cell lung cancer reveal ancestry-specific co-alterations with therapeutic implications

Abstract 3651: Mutational analysis and spatial phenotyping to decipher racial disparities in pancreatic adenocarcinoma

Abstract C172: Diversifying translational research models to address outcomes disparities in lung cancer

Abstract C026: Pharmacogenetics of pancreatic ductal adenocarcinoma: A review of racial disparities

Abstract 1948: Novel insights into lung cancer & chronic obstructive pulmonary disease racial disparities

Abstract 102: Clinicopathological and Molecular Characteristics, Treatment Patterns, and Outcomes in Patients with KRAS P.g12c-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC) in the AACR Project GENIE Database

Abstract 6129: Emerging disparities in the clinical actionability landscape for patients with inferred African ancestry

Abstract PR001: A comparison of modeling approaches to assess the interplay of social, behavioral, and environmental factors on lung cancer racial disparities